Another strategy has been active surveillance to detect all n ew cases of acute f1accid paralysis followed by rapid investigation to establish a diagnosis and. if needed. by 'mop-up· operations with OPV. In 1991, only nine confirmed cases of wild poliomyelitis were identified in the An1ericas (eight from Colombia and one from Peru). Although the initial target date has passed, PAHO is leading the world towards global eradication of wild poliomyelitis. Since September 1991 no case of wild indigenous poliomyelitis has been detected in the An1ericas.
Between 1949 and 1991 surveillance for paralytic poliomyelitis in Canada revealed 15.498 cases, 70% of whi ch occu rred during the prevaccin e period 1949-54 . These cases can be epidemiologically classified in to two groups: nonvaccine-associated. ie. caused by wild poliomyelitis viruses (endemic or imported): or suspected vaccine-associated, either among OPV recipients or contacts. In recent years . infection due to wild poliomyelitis viruses has been rare. From 1965-91. 53 cases of paralytic poliomyelitis were reported in Canada (Figure 1) . The most recent ,vild cases were associated with imported virus. The last case of wild indigenou s poliomyelitis occurred in 1977. Can ada, therefore. has not had an indigenous case in 15 years -a tremendous achievement. Actually, the PAHO and Canadian polio- There a re currently four components to the surveillance of poliomyelitis and flaccid paralysis in Canada: surveillance of the disease through the Canadian Communicable Disease Surveillance System, surveillance of vaccine-associated advers e events, an active pediatric hospital network surveillance system and a review of all cases of Guillain-Barre syndrome from hospital disch arge databases. Clearly, except for the first traditional component, the dynamic force h as been the surveillance of a dverse vaccine reaction s . As recommended by U1e Advisory Committee on Epidemiology (1) . surveillance of poliomyelitis requires adequate investigation of all clinically compatible cases. Multiple stool and other clinical specimens should be collected as soon as possible (at least within two weeks of symptom onset) and rapidly transported to a recognized viral la boratory witl1 documentation of maintenance of the cold ch ain, adequate neurological assessment and follow-up to establish neurological deficit lasting at least 60 days. Cases s h ould be reported as soon as s uspected.
However. based on recent examples . it is clear that these recommendations h ave not been fully applied. We can and must do better. Because of the rarity of paralytic poliomyelitis in Canada today, other conditions (such as Guillain-Barre syndrome) a r e often thought of before polio when diagnosing. The two last cases that occurred among adults in 1989 were finally classified as possible vaccine-associated cases of paralytic poliomyelitis (2) . Due to tl1e lack of timely and thorough investigation of these cases (particularly regarding stool samples) both of these cases would h ave been classified as 'polio compatible' by PAJ-10 standards. It is very disconcerting that clinically compatible cases of paralytic poliomyelitis are not thoroughly and timely investigated. This poses three major risks: missing the opportunity for immediate control measures following a genuine case of wild poliomyelitis (the possibility of occasional importation of the virus requires continual vigilant surveillance for paralytic poliomyelitis in Canada); the impossibility for Canada to be certified free from indigenous poliomyelitis and be acknowledged for its efforts; and the risk to overclassify cases as vaccine-associated (that might actually be related to other enteroviruses) which could lead to an unusually high rate of vaccine-associated paralytic poliomyelitis, decreasing confidence in the vaccine.
To counteract the feeling of complacency resulting from forgetting the disease when indigenous cases have long disappeared, a general effort involving health care providers, public health officials and laboratory virologists to increase awaren ess and program support for the investigation of cases of acute flaccid paralysis is 
